UCB reportedly gets bids for Kremers Urban unit from Cipla and Lupin

After having to call off a $1.5 billion deal last year to sell its U.S.-based generics business, Belgium's UCB has new bidders for the unit that reportedly include India's Cipla and Lupin. Sources tell Bloomberg that the two Indian drugmakers were among others to make first-round bids for Kremers Urban Pharmaceuticals. UCB in December canceled its deal with private equity investors Advent International and Avista Capital Partners after the FDA asked Kremers Urban for an additional study on its copy of Johnson & Johnson's ($JNJ) Concerta pill for attention deficit hyperactivity disorder (ADHD) to insure its equivalency. UCB said it needed to clear up the regulatory issues. Report | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.